

REMARKS

The drawings are objected to under 37 C.F.R. §1.83(a). The Examiner indicates that the mapping 22 and treatment 88 or 90 electrodes located on the support member 18 must be shown. Applicant notes that these features are illustrated, e.g., in Figs. 2, 3, 5B, 11, 12, and 18A-D. Therefore, Applicant respectfully requests that this objection be withdrawn.

Claims 74-106 have been canceled.

New claims 107-114 are presented for prosecution. No new matter has been added.

Claims 107-114 remain in the application. Of these, claims 107 and 111 are independent apparatus claims.

Claims 76-79 and 93-95 are rejected under 35 U.S.C. §101 as directed to non-statutory subject matter. These claims have been canceled. Applicant does not believe this rejection to be applicable to new claims 74-106.

Claims 83-87 and 98-102 are rejected under 35 U.S.C. §112, first paragraph. These claims have been canceled. With respect to new claims 74-106, applicant notes that a plurality of mapping 22 and treatment electrodes 88 or 90 are disclosed in the specification, e.g., at Page 22, Line 20 to Page 23, Line 4. The claimed features are shown, e.g., in Figs. 2, 3 and 18A-D. Further, as noted at Page 15, Lines 14-15 of the specification, mapping electrodes 22 can also be used as treatment electrodes 88.

Claims 74-103 are rejected under 35 U.S.C. §112, second paragraph. These claims have been canceled. Applicant does not believe this rejection to be applicable to new claims 74-106.


Claims 74-82, 86-97 and 101-104 are rejected in various combinations under 35 U.S.C. §102(b) as anticipated by Avitall U.S. Patent No. 5,263,493 (Avitall '493) or Avitall U.S. Patent No. 5,403,311 (Avitall '311) and under 35 U.S.C. §103(a) over Avitall '493 in view of Imran U.S. Patent No. 5,156,151 (Imran '151). These claims have been canceled. With respect to new claims 107-114, the cited references disclose systems providing a plurality of electrodes. However, the cited references, alone or in combination, do not teach or suggest a system having an electrode that is deployable into tissue, i.e., tissue-piercing, and operable to map tissue, ablate tissue, or both.

Claims 104-106 are rejected under the doctrine of obviousness-type double patenting over claims 1-88 of U.S. Patent No. 6,056,744 (the '744 Patent). These claims have been canceled. Applicant does not believe that new claims 107-114 present a double patenting problem with respect to the '744 Patent.

Serial No. 09/924,935
Amendment A

Allowance of claims 107-114 is respectfully requested.

Respectfully submitted,

By 
Daniel D. Ryan
Registration No. 29,243

RYAN KROMHOLZ & MANION, S.C.
P.O. Box 26618
Milwaukee, Wisconsin 53226-0618
February 26, 2003
924935a.ldr